BioCryst Pharmaceuticals, Inc. (BCRX) Stock Price & Analysis
BioCryst Pharmaceuticals, Inc. (BCRX) closed at USD 7.65 on Friday, October 23, 2026, down 1.67% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 7.78; the Oct 23, 2026 session ranged USD 7.52–7.76 on volume of 2,745,636 shares. Market capitalization is $1.95B, with a 52-week range of USD 6.23–11.22 (NMS). Source: Nexqual, retrieved October 24, 2026 at 17:55 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BCRX.md
Key facts (BCRX)
- Last four reported quarters (through Jun 30, 2026): revenue $941M, net income -$385M (-40.9% margin), free cash flow $373M (SEC filings).
- Insider open-market sales, last ~7 months: 2 Form 4 filings, $697K; 1 not under a Rule 10b5-1 plan ($100K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.00 on a 1–5 scale) (11 analysts), mean target USD 20.55 (range 11–32).
- Total return with dividends: 1Y +6.3% vs S&P 500 +13.4%; 5Y -48.8% vs S&P 500 +76.9%.
- Next earnings: 2026-11-04, EPS estimate USD 0.12, revenue estimate $166M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (BCRX)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $157M | $271M | $331M | $451M | $875M | $941M |
| Gross profit | $150M | $264M | $327M | $438M | $856M | — |
| Operating income | -$178M | -$148M | -$104M | -$2.5M | $341M | -$313M |
| Net income | -$184M | -$247M | -$227M | -$88.9M | $264M | -$385M |
| EPS (diluted) | -$1.03 | -$1.33 | -$1.18 | -$0.43 | $1.21 | — |
| Free cash flow | -$145M | -$163M | -$97.3M | -$53.1M | $345M | $373M |
| Gross margin | 95.4% | 97.6% | 98.6% | 97.3% | 97.8% | — |
| Operating margin | -113.1% | -54.8% | -31.3% | -0.6% | 39.0% | -33.3% |
| Net margin | -117.1% | -91.2% | -68.4% | -19.7% | 30.2% | -40.9% |
| Revenue growth | +782.4% | +72.3% | +22.4% | +36.0% | +94.1% | — |
| Cash + short-term investments | $508M | $424M | $389M | $321M | $275M | — |
| Total debt | $298M | $232M | $303M | $315M | $0K | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (BCRX)
P/S 2.1x · EV/Sales 2.1x · P/FCF 5.2x · FCF yield 19.10% · Earnings yield -19.68% · Net debt $42.8M · EV $2.00B
P/E at fiscal year-ends: Dec 2025 6.5x.
Insider sales (SEC Form 4, open-market, last ~7 months) (BCRX)
1 of 2 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-05-18 | McKee Amy E | Director | 11,180 | $100K | 26.3% | No | Too little history (no open-market trades in 2023 or 2025) |
| 2026-05-13 | Barnes Alane P | Chief Legal Officer | 62,500 | $596K | 13.5% | Yes (adopted August 13, 2025) | Too little history (no open-market trades in 2023) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (BCRX)
Consensus Buy (mean 2.00 on a 1–5 scale), 11 analysts; mean target USD 20.55 (low 11, high 32).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-30 | JP Morgan | Target raised | Neutral | $12 → $13 |
| 2026-09-10 | RBC Capital | Downgrade | Outperform → Sector Perform | $13 → $11 |
| 2026-09-08 | Needham | Reiterated | Buy | $16 |
| 2026-08-06 | RBC Capital | Target lowered | Outperform | $14 → $13 |
| 2026-08-06 | Wedbush | Target lowered | Outperform | $21 → $20 |
| 2026-07-07 | RBC Capital | Target raised | Outperform | $13 → $14 |
| 2026-06-30 | HC Wainwright & Co. | Maintained | Buy | $32 |
| 2026-06-30 | Cantor Fitzgerald | Target raised | Overweight | $27 → $29 |
Total return (dividends reinvested) (BCRX)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +6.3% | -48.8% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | +6.3% | -12.5% |
| Volatility (annualized) | 47.5% | 53.8% |
| Max drawdown | -31.1% (Jul 2026→Oct 2026) | -77.8% (Feb 2022→Apr 2024) |
BCRX revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| ORLADEYO | $158.2M | 72.5% | +0.9% |
| Product | $157.5M | 72.2% | -3.0% |
| License and other revenues | $60.7M | 27.8% | +6480.4% |
| License and other revenues | $60.0M | 27.5% | +821.5% |
| Total revenue | $218.3M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
BCRX suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Torii Pharmaceutical | “•plans, programs, progress and potential success of our collaborations, including, for example, with Torii Pharmaceutical Co., Ltd. ("Torii") for ORLADEYO in Japan and Shionogi & Co., Ltd. ("Shionogi") and Green Cross Corporation ("Green Cross") for peramivir in their territories;” |
| Partner | Green Cross | “•plans, programs, progress and potential success of our collaborations, including, for example, with Torii Pharmaceutical Co., Ltd. ("Torii") for ORLADEYO in Japan and Shionogi & Co., Ltd. ("Shionogi") and Green Cross Corporation ("Green Cross") for peramivir in their territories;” |
| Partner | Japan and Shionogi & | “•plans, programs, progress and potential success of our collaborations, including, for example, with Torii Pharmaceutical Co., Ltd. ("Torii") for ORLADEYO in Japan and Shionogi & Co., Ltd. ("Shionogi") and Green Cross Corporation ("Green Cross") for peramivir in their territories;” |
| Partner | BioCryst Ireland | “Additionally, we entered into a global brand and support agreement with BioCryst Ireland, which provides for coordination of brand and regulatory activities between us and BioCryst Ireland regarding ORLADEYO products.” |
| Partner | Clearside Biomedical | “Currently, we have established collaborative relationships, including with, among others, third-party distributors for ORLADEYO in certain markets, with Torii for ORLADEYO in Japan, with Neopharmed for the commercialization of ORLADEYO in Europe, with each of Shionogi and Green Cross for the development and commercialization of peramivir, and with Clearside for the development of avoralstat with Clearside's SCS Mi…” |
| Partner | Pint Pharma | “We have an exclusive collaboration with Pint Pharma GmbH ("Pint Pharma") to register and promote ORLADEYO in the pan-Latin America region.” |
| Partner | Swixx BioPharma | “On January 23, 2023, we announced that we entered into a collaboration with Swixx BioPharma AG ("Swixx") to commercialize ORLADEYO in Central and Eastern Europe ("CEE").” |
| Partner | Neopharmed Gentili | “Pursuant to the Stock Purchase Agreement with Neopharmed, we transferred the agreement with Swixx to Neopharmed.” |
| Partner | General | “Our and our partners' activities related to approved products or, following their regulatory approval (if applicable), any of our product candidates under development, are subject to regulatory and law enforcement authorities in the United States (including the FDA, the Federal Trade Commission, the Department of Justice ("DOJ"), the HHS, Office of Inspector General, and state and local governments) and their fore…” |
| Partner | LP and BPCR | “On April 17, 2023, we entered into a $450.0 million Loan Agreement (the "Pharmakon Loan Agreement") with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership, as lenders, and BioPharma Credit PLC, as collateral agent for the lenders.” |
| Competitor | Merck (MRK) | “In addition, we are aware of a number of products in development that would offer alternatives to anti-VEGF therapies, which could affect the competitive environment for our products, including Rezolute Inc.'s RZ402, Merck & Co. Inc.'s Restoret™ (MK-3000, formerly EYE103), Ocular Therapeutix™'s AXPAXLI ™ and EyePoint Pharmaceutical Inc.'s DURAVYU™ (formerly EYP-1901).” |
Quoted from the company's 10-K filed Feb 26, 2026.
BCRX company outlook (results filed Aug 5, 2026)
- “Financial Outlook for 2026 The company maintained its outlook for full year 2026 global net ORLADEYO revenue of $625 million to $645 million.”
- “The company raised the full year 2026 total revenue outlook, including RAPIVAB ® (peramivir injection) and revenue from the licensing of navenibart European rights, to $690 million to $715 million.”
- “In June, the company improved its outlook for full year 2026 non-GAAP operating expenses, excluding stock-based compensation, restructuring, and transaction-related costs, to $420 million to $440 million, due to the announced plans to discontinue internal discovery programs and close the Birmingham facility.”
Quoted word-for-word from the SEC 8-K results press release.
BCRX analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.12 | $0.13 | -8.0% | $165.7M | 2 |
| Next quarter (ends Dec 2026) | $0.13 | $0.16 | -18.8% | $169.8M | 2 |
| Current fiscal year (ends Dec 2026) | $0.75 | $0.66 | +13.6% | $710.1M | 2 |
| Next fiscal year (ends Dec 2027) | $0.82 | $1.00 | -17.5% | $736.4M | 2 |
BCRX options: expected move
Options price a move of about ±14.4% (±$1.10) by Nov 20, 2026, which includes earnings on Nov 4, 2026. Over the last 8 reports the stock moved ±7.6% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 27 | 61.9% | ±14.4% |
| Dec 18, 2026 | 55 | 42.9% | ±17.2% |
| Jan 15, 2027 | 83 | 58.0% | ±22.9% |
| Mar 19, 2027 | 146 | 58.1% | ±37.6% |
| Apr 16, 2027 | 174 | 62.9% | ±43.5% |
30-day implied volatility 55.6% vs 35% realized over the last 30 trading days. Put/call ratio (volume) 0.6. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 24, 2026 at 17:55 UTC)
| Price | USD 7.65 |
|---|---|
| Change | ▼ 1.67% (down) |
| Previous Close | USD 7.78 |
| Open | USD 7.71 |
| Day Range | USD 7.52 – 7.76 |
| 52-Week Range | USD 6.23 – 11.22 |
| Volume | 2,745,636 shares |
| Market Cap | $1.95B |
| Exchange | NMS |
Technical Analysis (BCRX)
Nexqual's technical model rates BCRX "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 24, 2026 at 17:55 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 35.09 (neutral) |
| vs SMA50 | Below (USD 8.79) |
| MACD | -0.27 (negative) |
Analyst Ratings (BCRX)
Wall Street analysts rate BCRX "Buy" based on 11 analysts, with a mean price target of USD 20.55 (range USD 11–32), per Nexqual as of October 24, 2026 at 17:55 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 20.55 |
| High Target | USD 32 |
| Low Target | USD 11 |
| Buy / Hold / Sell | 9 / 2 / 0 |
Earnings (BCRX)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD 0.12 |
| Revenue Estimate | $165.68M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.35 vs est 0.24 ▲ beat |
| 2026-03-31 | USD 0.14 vs est 0.11 ▲ beat |
| 2025-12-31 | USD 0.21 vs est 0.07 ▲ beat |
| 2025-09-30 | USD 0.16 vs est 0.07 ▲ beat |
Source: Nexqual, October 24, 2026 at 17:55 UTC.
Financials & Fundamentals (BCRX)
| Total Revenue | $940.61M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +33.60% |
| Gross Margin | +77.39% |
| Operating Margin | +45.12% |
| Profit Margin | -40.90% |
| Current Ratio | 2.32 |
| Total Cash | $352.57M |
| Total Debt | $836.64M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $373.38M (39.7% of revenue) |
Source: Nexqual, October 24, 2026 at 17:55 UTC.
Financial Health Score (BCRX)
Nexqual rates BioCryst Pharmaceuticals, Inc.'s overall financial health "Solid" across five dimensions, as of October 24, 2026 at 17:55 UTC.
| Growth | Strong — Revenue +94% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 77%, operating 45% (last 12 months) |
| Balance Sheet | Mixed — $353M cash and investments vs $395M debt (Jun 2026, SEC) |
| Cash Flow | Strong — FCF $373M (last 4 quarters to Jun 2026, SEC), 40% margin |
| Efficiency | Mixed — No data |
Ownership (BCRX)
| Insider Ownership | +1.28% |
|---|---|
| Institutional Ownership | +105.82% |
| Shares Outstanding | 255.54M |
| Float | 222.32M |
| Short % of Float | +10.84% |
Source: Nexqual, October 24, 2026 at 17:55 UTC.
Leadership (BCRX)
BioCryst Pharmaceuticals, Inc. is led by Charles K. Gayer, CEO, President & Director, per Nexqual as of October 24, 2026 at 17:55 UTC.
| CEO, President & Director | Charles K. Gayer |
|---|---|
| CFO & Head of Corporate Development | Babar Ghias |
| Chief Scientific Officer | David W. Jenkins M.A. |
Major Backers & Investors (BCRX)
Notable institutional backers of BioCryst Pharmaceuticals, Inc. include RA Capital Management, L.P., Deerfield Management Company, L.P, TCG Crossover Management, LLC, according to Nexqual as of October 24, 2026 at 17:55 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RA Capital Management, L.P. | 6.19% |
| Deerfield Management Company, L.P | 5.91% |
| TCG Crossover Management, LLC | 4.31% |
| Perceptive Advisors Llc | 4.03% |
| Jupiter Topco LLC | 3.73% |
| Vestal Point Capital, LP | 3.25% |
| abrdn Healthcare Investors | 1.73% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.35% |
| Vanguard Group | 8.81% |
| State Street | 5.94% |
Source: Nexqual, October 24, 2026 at 17:55 UTC.
From BioCryst Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Based on proprietary analyses of HAE prevalence and market research studies with HAE patients, physicians, and payors in the United States and Europe, and five full years of commercialization experience with ORLADEYO in the United States from 2021 through 2025, we anticipate that the global commercial market for ORLADEYO has the potential to reach a global peak of $1 billion in annual net ORLADEYO revenues.
- Our ability to maintain and solidify our proprietary position for our technology will depend on our success in obtaining effective patent claims and enforcing those claims once granted.
- We own or have rights to certain proprietary information, proprietary technology, issued and allowed patents and patent applications which relate to compounds we are developing.
- We actively seek, when appropriate, protection for our products, proprietary technology, and proprietary information by means of U.S. and foreign patents, trademarks, and contractual arrangements.
Partnerships
- On November 5, 2019, we entered into a Commercialization and License Agreement with Torii (the "Original Torii Agreement"), granting Torii the exclusive right to commercialize ORLADEYO for the prevention of HAE attacks in Japan.
- On October 1, 2025, we also entered into a supply agreement with BioCryst Ireland, pursuant to which we will be the exclusive supplier of ORLADEYO products to BioCryst Ireland for commercialization in the territory.
Legal & Regulatory Risks (Item 1A, quoted)
- We are subject to various laws and regulations related to our products and product candidates, and if we or our partners do not comply with these laws and regulations, we could face substantial penalties.
- We are responsible for reporting adverse drug or biological product experiences, have responsibility for certain post-approval studies, and may have responsibilities and costs related to a recall or withdrawal of our products from sale in the jurisdictions in which they are approved.
- The principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services.
- We cannot predict the likelihood, nature or extent of government regulation or other measures that may arise from future legislation or administrative or executive action, either in the United States or abroad.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUPN | Supernus Pharmaceuticals, Inc. | USD 40.7 | ▼ 3.26% |
| BHC | Bausch Health Companies Inc. | USD 6.44 | ▼ 0.77% |
| HCM | HUTCHMED (China) Limited | USD 14.36 | ▲ 0.56% |
| AMLX | Amylyx Pharmaceuticals, Inc. | USD 27.2 | ▼ 4.8% |
| RGC | Regencell Bioscience Holdings L | USD 7.67 | ▼ 21.81% |
| LQDA | Liquidia Corporation | USD 42.65 | ▲ 7.46% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 17:55 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt